GULHANE MEDICAL JOURNAL 2017 , Vol 59 , Issue 1
Sorefenib inhibits the expressions of heat shock protein70 gene on multiple myeloma (RPMI-8226) and plasma cell leukemia (ARH-77) cell lines
Zehra Dilşad Çoban1,Hakan Kayır2,Şefik Güran3
1The General Staff of Turkey, Department of Health Kızılay-Ankara
2Yüksek İhtisas University, Medical Faculty, Department of Pharmacology Sıhhiye-Ankara
3Health Sciences University, Gülhane Medical Faculty, Department of Medical Biology
DOI : 10.5455/gulhane.233425 Sorafenib is an anticancer drug used in solid tumors. It inhibits many tirosine kinases in the cell and causes the tumor cell undergone to apopitosis. Multiple myeloma and plasma cell leukemia both are plasma cell dyscrasias and have limited treatment procedures. Heat shock proteins are the important part of the cell's machinery for protein folding and help to protect cells from stress. Heat shock proteins are high in tumor cells in some cases. The over-expressions of these proteins increase the tumor growth and metastatic potential. In our study, the cytotoxic effects of Sorafenib were analyzed on multiple myeloma and plasma cell leukemia cell lines with trypan blue and MTT analyses. The LD50 value is found as 12 μM in RPMI-8226 cells and 9 μM in ARH-77 cells by using MTT cell proliferation assay. Cell viability assay findings with trypan blue were supported the MTT analyses results. In multiple myeloma cell line 89% viability was found with sorafenib. In plasma cell leukemia cell line, it was found as 80%. Also the gene expression analyses of heat shock proteins70 and 90 were studied on these cell lines in our study. Sorafenib inhibited heat shock protein70 gene expressions in these two cell lines in a dose- and time-dependent manner. So, sorafenib has cytotoxic affect by inducing apopitosis on heat shock protein70 gene in multiple myeloma and plasma cell leukemia cell lines. Keywords : Sorefenib, multipl myeloma, plasma cell leukemia, heat shock protein70, heat shock protein90